Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Bioavailability Study Design: Single Versus Multiple Dose Studies01:11

Bioavailability Study Design: Single Versus Multiple Dose Studies

350
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
350
Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs01:20

Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs

386
Bioequivalence experimental study designs are crucial methodologies used in evaluating and comparing the bioavailability of different drug products. These designs are categorized into various types: completely randomized, randomized block, repeated measures, cross and carry-over, and Latin square designs.Completely randomized designs involve randomly allocating treatments to all subjects participating in the experiment. This allocation is achieved by assigning unique random numbers to subjects...
386
Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs01:15

Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs

395
Bioequivalence experimental study designs play a pivotal role in testing the effectiveness of various treatments. Key among these are the repeated measures, cross-over, carry-over, and Latin square designs. In the repeated measures design, each subject receives all treatments, allowing for temporal comparisons. This type of design is useful in reducing variability but requires careful planning to avoid bias.The cross-over design, an economical method, involves sequential administration of...
395
Dosage Regimens: Designs and Approaches01:28

Dosage Regimens: Designs and Approaches

566
Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...
566
Dosage Regimen Designs: Nomograms and Tabulations01:23

Dosage Regimen Designs: Nomograms and Tabulations

319
Nomograms and tabulations are vital tools used by clinicians to design accurate and individualized dosage regimens. These instruments provide a straightforward method for adjusting dosages based on individual patient characteristics, including age, weight, and physiological condition. The foundation of a drug's nomogram is population pharmacokinetic data collected and analyzed using specific models. This data simplifies complex equations, presenting them diagrammatically or tabularly for easy...
319
Determination of Multiple Dosing Parameters: Loading and Maintenance Doses01:25

Determination of Multiple Dosing Parameters: Loading and Maintenance Doses

369
A loading dose is an essential pharmacological strategy to rapidly achieve the target plasma drug concentration necessary for an immediate therapeutic effect. This approach is especially critical for drugs characterized by slow absorption or extended half-lives, where delaying therapeutic plasma levels could compromise treatment outcomes. By administering a loading dose, clinicians ensure a prompt onset of drug action, even for agents with complex pharmacokinetic profiles.Achieving steady-state...
369

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Letrozole Alters Transcriptomic Profiles in Infrapatellar Fat Pad From Female Mice: Possible Involvement of Interleukins in Aromatase Inhibitor-Induced Arthralgias.

Journal of applied toxicology : JAT·2026
Same author

Assumption-Agnostic Deep Learning Framework for Holistic Clinical Trial Monitoring.

Therapeutic innovation & regulatory science·2026
Same author

An Anti-Inflammatory and Pro-Angiogenic Porous Aloe Polysaccharide-Collagen Dressing Accelerates Wound Healing.

ACS applied bio materials·2025
Same author

Fruquintinib in less pretreated patients: Multivariate profile-matching analysis of FRESCO-2 to FRESCO.

European journal of cancer (Oxford, England : 1990)·2025
Same author

A Flexible Seamless Phase 2/3 Design With Biomarker-Driven Subgroup Enrichment and Sample Size Re-Estimation.

Pharmaceutical statistics·2025
Same author

Understanding motives for illicit medicinal cannabis use: an exploratory analysis in a medical cannabis program.

Journal of cannabis research·2025
Same journal

Leveraging external controls in clinical trials: estimands, estimation, assumptions.

Journal of biopharmaceutical statistics·2026
Same journal

Comparison of flexible parametric modeling and nonparametric methods to estimate restricted mean survival time: A simulation study.

Journal of biopharmaceutical statistics·2026
Same journal

Simulated treatment comparisons with jackknife pseudo values for estimating population-adjusted marginal treatment effects.

Journal of biopharmaceutical statistics·2026
Same journal

Sample sizes for randomized controlled trials utilizing Bayesian response adaptive randomization for continuous outcomes.

Journal of biopharmaceutical statistics·2026
Same journal

Handing missing data using multiple imputation in hybrid control clinical trials with modified power prior.

Journal of biopharmaceutical statistics·2026
Same journal

A doubly robust estimator for unanchored indirect treatment comparisons: Development and evaluation using simulated and case-study data.

Journal of biopharmaceutical statistics·2026
查看所有相关文章

相关实验视频

Updated: Apr 12, 2026

Cryo-EM and Single-Particle Analysis with Scipion
09:06

Cryo-EM and Single-Particle Analysis with Scipion

Published on: May 29, 2021

4.3K

M-DODII:贝叶斯剂量优化设计,用于随机二期研究,多种适应症.

Sasha Amdur Kravets1, Ziji Yu2, Rachael Liu2

  • 1Statistics, Oncology, Eli Lilly and Company, Indianapolis, IN, USA, formerly at Division of Epidemiology and Biostatistics, School of Public Health, University of Illinois Chicago, Indianapolis, IN, USA.

Journal of biopharmaceutical statistics
|November 28, 2025
PubMed
概括
此摘要是机器生成的。

一个新的贝叶斯设计,M-DODII,优化药物剂量,并同时选择用于瘤学试验的指示. 这种方法提高了剂量选择的准确性,并减少了与传统方法相比的样本大小.

关键词:
贝叶斯适应性设计是贝叶斯的适应性设计.剂量优化的优化该项目是Optimus项目.总体协议的总体协议第二阶段临床试验.

更多相关视频

Dissecting Mechanoenzymatic Properties of Processive Myosins with Ultrafast Force-Clamp Spectroscopy
09:38

Dissecting Mechanoenzymatic Properties of Processive Myosins with Ultrafast Force-Clamp Spectroscopy

Published on: July 1, 2021

1.6K
A Multimodal Wide-Field Fourier-Transform Raman Microscope
06:46

A Multimodal Wide-Field Fourier-Transform Raman Microscope

Published on: December 30, 2025

16

相关实验视频

Last Updated: Apr 12, 2026

Cryo-EM and Single-Particle Analysis with Scipion
09:06

Cryo-EM and Single-Particle Analysis with Scipion

Published on: May 29, 2021

4.3K
Dissecting Mechanoenzymatic Properties of Processive Myosins with Ultrafast Force-Clamp Spectroscopy
09:38

Dissecting Mechanoenzymatic Properties of Processive Myosins with Ultrafast Force-Clamp Spectroscopy

Published on: July 1, 2021

1.6K
A Multimodal Wide-Field Fourier-Transform Raman Microscope
06:46

A Multimodal Wide-Field Fourier-Transform Raman Microscope

Published on: December 30, 2025

16

科学领域:

  • 在瘤学瘤学.
  • 临床试验设计 临床试验设计
  • 生物统计学 生物统计学

背景情况:

  • 瘤药物开发正在转向新型药物,如分子向疗法 (MTA) 和免疫疗法.
  • 传统的剂量优化方法可能不适合这些新型疗法,需要新的方法.
  • 当前的方法经常无法在早期试验中同时解决剂量优化和适应症选择的问题.

研究的目的:

  • 提出一个新的贝叶斯剂量优化设计,用于随机的多种指示的II期试验 (M-DODII).
  • 整合贝叶斯连续监测和贝叶斯选择赢家策略,同时选择剂量和适应症.
  • 在模拟研究中评估M-DODII的操作特性.

主要方法:

  • M-DODII设计使用了有效性和毒性终点.
  • 它采用贝叶斯的持续监测和贝叶斯的选择胜利者的方法.
  • 进行了模拟研究,以评估性能与其他适应性设计相比.

主要成果:

  • M-DODII表现出良好的操作特性,并有控制的选择错误.
  • 拟议的设计显示,选择低于最佳剂量的可能性较低.
  • M-DODII实现了选择最佳剂量的更高概率,并减少了总样本大小.

结论:

  • 在早期瘤学试验中,M-DODII为同时优化剂量和指示选择提供了有效的解决方案.
  • 该设计通过提高剂量选择的准确性和效率来改进现有的适应性方法.
  • 这种贝叶斯式方法对于推进新型癌症疗法的发展至关重要.